OPKO Health (FRA:XCY) FFO


FRA:XCY OPKO Health Inc FRA:XCY
52 GF Score
Price €1.27
GF Value €0.89
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is OPKO Health FFO?

FFO (Funds from operations) only applies to REITs.

FRA:XCY
52GF Score
OPKO Health Inc FRA:XCY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OPKO Health (FRA:XCY) Overvalued in 2026?

Based on GuruFocus' analysis, OPKO Health stock appears to be overvalued. The current stock price of €1.27 is trading 42.7% above its estimated GF Value™ of €0.89. GuruFocus considers OPKO Health to be Significantly Overvalued.

Key valuation signals for FRA:XCY:

  • FFO:
  • GF Value™: €0.89 vs. price of €1.27 (42.7% above fair value)
  • GF Score™: 52/100 with 7 warning signs

No single metric tells the full story. See the FRA:XCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OPKO Health Business Description

Address 4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
52GF Score

Get the complete analysis for FRA:XCY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.27
Price
€0.89
GF Value